Gemtuzumab Ozogamicin (Mylotarg®)
Dokument
Fact Sheet
Spezifizierung
Akute Myeloische Leukämie (AML)
» neu diagnostiziert, ungeeignet für intensive Chemotherapie
» alle (Meta-Analyse)
Stand
Januar 2021
Dies ist die aktuell gültige Version des Dokuments
1Gemtuzumab Ozogamicin, AML, newly diagnosed, all (meta-analysis)
1 N - number of patients2 RR - remission rate, in %4 PFS - progression-free survival in months11 SR - sustained response14 results for control, results for new therapy15 hazard ratio for new therapy16 n. s. not significant19 Complete Remission Rate (CR + CRi)20 Survival rate after 5 years
